Skip to content
The Kids Research Institute Australia logo
Donate

Search

Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastoris

The house dust mite allergen Der p 2 is one of the most important indoor allergens associated with allergic disease.

The cat lipocalin Fel d 7 and its cross-reactivity with the dog lipocalin Can f 1

Fel d 7 is a common allergen in a Swedish cat-sensitized population that cross-reacts with Can f 1

Protective anti-outer membrane protein immunity against Pasteurella pneumotropica infection of mice

The proteins examined were the homologues of the P4, P6, P26, and D15 proteins of Haemophilus influenzae.

Recombinant house dust mite allergens

House dust mites (HDM) are a globally important source of allergen responsible for the sensitization of more than 50% of allergic patients.

Species-Specific and Cross-Reactive IgG1 Antibody Binding to Viral Capsid Protein 1 (VP1) Antigens of Human Rhinovirus Species A, B and C

Human rhinoviruses (HRV) are associated with upper and lower respiratory illnesses, including severe infections causing hospitalization in both children...

Antibacterial antibody responses associated with the development of asthma in house dust mite-sensitised and non-sensitised children

We aimed to measure the antibody development to 2 bacteria in a birth cohort at high risk of allergic disease, and to assess which responses are asthma-linked.

Early aberrant antibody responses of aeroallergen sensitised people to subclinical bacterial infection

Early aberrant antibody responses, aeroallergen sensitised people, subclinical bacterial infection

Barriers and Considerations for Diagnosing Rare Diseases in Indigenous Populations

Advances in omics and specifically genomic technologies are increasingly transforming rare disease diagnosis. However, the benefits of these advances are disproportionately experienced within and between populations, with Indigenous populations frequently experiencing diagnostic and therapeutic inequities. The International Rare Disease Research Consortium (IRDiRC) multi-stakeholder partnership has been advancing toward the vision of all people living with a rare disease receiving an accurate diagnosis, care, and available therapy within 1 year of coming to medical attention. In order to further progress toward this vision, IRDiRC has created a taskforce to explore the access barriers to diagnosis of rare genetic diseases faced by Indigenous peoples, with a view of developing recommendations to overcome them.

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.